Lappe Mark's Form 4 filing
Inhibrx Biosciences, Inc. (INBX) · filed Sep 10, 2024
- Accession no.
- 0002007919-24-000045
- Filed
- Sep 10, 2024
- Trade date
- Sep 6-10, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market purchases total $671.1K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lappe MarkCIK 0001366074 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 6, 2024 | Common Stock | PPurchaseAcquired | +26,000 | $15.29F1 | +$397,540 | 647,548 | Indirect | |
| Sep 9, 2024 | Common Stock | PPurchaseAcquired | +9,500 | $15.21F3 | +$144,495 | 657,048 | Indirect | |
| Sep 10, 2024 | Common Stock | PPurchaseAcquired | +8,500 | $15.19F4 | +$129,115 | 665,548 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The shares were purchased in multiple transactions at prices ranging from $15.04 to $15.70, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
Referenced by the price of 1 transaction in Table I.
- F3
The shares were purchased in multiple transactions at prices ranging from $15.08 to $15.50, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
Referenced by the price of 1 transaction in Table I.
- F4
The shares were purchased in multiple transactions at prices ranging from $15.01 to $15.26, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
Referenced by the price of 1 transaction in Table I.